Consolidation Immunotherapy
2 clinical trials · Condition
◉ Watch Consolidation Immunotherapy
| Record | Firm | Date |
|---|---|---|
| Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients (NCT05758116) | Peking University Cancer Hospital & Institute | 2022-07-07 |
Track Consolidation Immunotherapy automatically
Every clearance here is in the API, with alerts when new ones post.